Gelesis rounds up $3.6M in fresh venture funds

Gelesis, a biotech startup focused on developing new obesity treatments, has raised $3.6 million, reports Globes. The new money brings its total take to date to $20 million. Gelesis was one of FierceBiotech's Fierce 15 in 2010. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.